MedTrace Logo

Integrated Biomarker And Imaging Study - 2

NCT00268996 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2018-03-20

Study results available
· View outcomes & findings →

Summary

IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.

Conditions

Interventions

DRUG

SB-480848

SB-480848 is available as enteric-coated, free-base micronized tablet

DRUG

SB-480848 matching placebo

Placebo is available as enteric-coated, free-base micronized tablet

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-10
Primary Completion
2007-08-28
Completion
2007-08-28

Countries

  • Austria
  • Belgium
  • Czechia
  • Denmark
  • France
  • Germany
  • Netherlands
  • Norway
  • Poland
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00268996 on ClinicalTrials.gov